Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.44 |
| ▸ | CES2 | O00748 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692564 | 0.93 | CES2 (0.46) | CES1CES2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL723380 | 0.83 | CES1 (0.50) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL26287322 | 0.83 | CES1 (0.50) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL17164988 | 0.83 | CYP1A2 (0.43) | ALDH1A1KDM4ESMN1; SMN2NOS1TSHR | |
| SCHEMBL11553559 | 0.82 | FAAH (0.61) | TP53KDM4ECYP1A2MAPTCYP2C19 | |
| SCHEMBL14478079 | 0.81 | CES2 (0.48) | CES1CES2ALDH1A1TP53CA1 | |
| Hydrochloric Acid SCHEMBL9509927 | 0.81 | CYP1A2 (0.46) | ALDH1A1KDM4ESMN1; SMN2NOS1TSHR | |
| SCHEMBL12457027 | 0.79 | CES1 (0.46) | CES1CES2ALDH1A1TP53CA1 | |
| SCHEMBL14166455 | 0.79 | CES2 (0.48) | CES1CES2ALDH1A1TP53KDM4E | |
| SCHEMBL13030803 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | CES1 1761/4885CES2 1965/4885ALDH1A1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.